Specific Small‐Molecule NIR‐II Fluorescence Imaging of Osteosarcoma and Lung Metastasis

Zhou, Hui; Yi, Wanrong; Li, Anguo; Wang, Bo; Ding, Qihang; Xue, Liru; Zeng, Xiaodong; Feng, Yanzhi; Li, Qianqian; Wang, Tian; Li, Yang; Cheng, Xiaoding; Tang, Lin; Deng, Zixin; Wu, Mingfu; Xiao, Yuling; Hong, Xuechuan

doi:10.1002/adhm.201901224

Cited by 62 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5d). The toxicity of H4-PEG-PT was determined in vitro with an MTT assay on 143B and L929 cells at different concentrations (2,4,8,16, and 32 µM) ( Fig. 5f).…”

Section: Resultsmentioning

confidence: 99%

“…In vitro bone-targeted assay. In order to evaluate the binding ability of H4-PEG-PT and H4, various amount of the probes (2,4,8,16,32, and 64 μM, 500 μL) were incubated with HA (10 mg), respectively, for 4 h at room temperature under mild stirring. Then, the mixture was centrifugated at 1200 rpm for 10 min and washed with 8-fold excess of PBS three times.…”

Section: Subcellular Distribution Of Cytochrome C (Cyto C)mentioning

confidence: 99%

“…luorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm) has been widely used in biological and biomedical research, because the light in this wavelength region is capable of deep penetration, and cellular autofluorescence is minimal [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] . Our initial progress toward the first small-molecule organic NIR-II dye entailed the formation of the fluorophore CH1055 from benzo-bis(1,2,5-thiadiazole) (BBTD), which absorbed light at~750 nm and fluoresced at 1055 nm [18][19][20] .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

NIR-II fluorophores have shown great promise for biomedical applications with superior in vivo optical properties. To date, few small-molecule NIR-II fluorophores have been discovered with donor-acceptor-donor (D-A-D) or symmetrical structures, and upconversion-mitochondria-targeted NIR-II dyes have not been reported. Herein, we report development of D-A type thiopyrylium-based NIR-II fluorophores with frequency upconversion luminescence (FUCL) at ~580 nm upon excitation at ~850 nm. H4-PEG-PT can not only quickly and effectively image mitochondria in live or fixed osteosarcoma cells with subcellular resolution at 1 nM, but also efficiently convert optical energy into heat, achieving mitochondria-targeted photothermal cancer therapy without ROS effects. H4-PEG-PT has been further evaluated in vivo and exhibited strong tumor uptake, specific NIR-II signals with high spatial and temporal resolution, and remarkable NIR-II image-guided photothermal therapy. This report presents the first D-A type thiopyrylium NIR-II theranostics for synchronous upconversion-mitochondria-targeted cell imaging, in vivo NIR-II osteosarcoma imaging and excellent photothermal efficiency.

show abstract

“…5d). The toxicity of H4-PEG-PT was determined in vitro with an MTT assay on 143B and L929 cells at different concentrations (2,4,8,16, and 32 µM) ( Fig. 5f).…”

Section: Resultsmentioning

confidence: 99%

Section: Subcellular Distribution Of Cytochrome C (Cyto C)mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Zhou et al designed and synthesized the two homologous forms of fluorescent probes CH1055-PEG-PT and CH1055-PEG-Affibody that show extremely promising results for targeting imaging of OSA and its lung organ metastasis, respectively. it’s found that the close to NIR-II imaging quality of CH1055-PEG-PT is way superior thereto of CT for the first in vivo 143B tumor imaging, and this probe-guided surgery for accurate surgery of 143B tumor [ 82 ].…”

Section: Diagnosis Of Human Osteosarcomamentioning

confidence: 99%

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

et al. 2021

View full text Add to dashboard Cite

Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones. OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients’ overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it.

show abstract

“…Although the combination of chemotherapy and surgery improve its prognosis, many patients still experience recurrence or metastasis [2]. Pulmonary metastasis is the most common cause of death for osteosarcoma patients [3]. Therefore, identifying reliable biomarkers for osteosarcoma metastasis and prognosis can provide attractive potential targets and prognostic evaluation.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of SP6 Correlates with Osteosarcoma Metastasis and Poor Prognosis

Li¹,

Wang²,

Zhao³

et al. 2020

JSO

View full text Add to dashboard Cite

Background: SP6 (Specificity protein 6) has been explored as a prospective biomarker in several cancers. In this research, the prognostic value of SP6 expression in osteosarcoma was predicted by bioinformatics analysis. Data were obtained from the Gene Expression Omnibus (GEO) database. Methods: Gene expression data and clinical materials were downloaded from the GSE21257 dataset. The mRNA expression of SP6 was compared between metastatic and non-metastatic tissues with the Wilcoxon rank-sum test, and the relationship between SP6 and clinicopathological characters was analysed using logistic regression. In addition, the correlation between SP6 and survival rate was assessed using KaplanMeier and Cox regression. Moreover, receiver operating characteristic (ROC) curve analysis was conducted to determine the prognostic merit of SP6 for osteosarcoma. The biological functions of SP6 were annotated and evaluated through gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA). Results: SP6 was significantly highly expressed in metastatic osteosarcoma tissues (p = 0.002). High SP6 expression showed a positive correlation with Huvos grade (OR = 6.60 for I vs. II, p = 0.028). The overall survival (OS) of the patients with high SP6 expression was significantly poorer than the low SP6 expression group (p = 0.027). The multivariate analysis revealed that SP6 expression (p = 0.002, HR = 15.40 (95% CI [2.84–83.44])) was independently correlated with OS. GSEA and GSVA showed that "spliceosome" and "base excision repair" were significantly upregulated in the high expression group of SP6. Conclusion: SP6 may serve an independent prognostic biomarker in osteosarcoma.

show abstract

Specific Small‐Molecule NIR‐II Fluorescence Imaging of Osteosarcoma and Lung Metastasis

Cited by 62 publications

References 45 publications

Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy

Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

Overexpression of SP6 Correlates with Osteosarcoma Metastasis and Poor Prognosis

Contact Info

Product

Resources

About